Teriparatide is a recombinant form of parathyroid hormone used for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture, as well as for men and women with osteoporosis associated with sustained high doses of glucocorticoid therapy [1]. Generic versions of teriparatide are available, offering a more affordable alternative to the original branded product, Forteo [2].
What is the difference between Forteo and generic teriparatide?
Forteo is the original brand-name medication containing teriparatide. Generic teriparatide products contain the same active ingredient as Forteo and are approved by the U.S. Food and Drug Administration (FDA) to be bioequivalent [3]. This means they are expected to have the same safety and efficacy profiles. The primary difference typically lies in the cost, with generics usually being significantly less expensive than the brand-name drug [2].
When does the patent for Forteo expire?
The patent exclusivity for Forteo has largely expired, allowing for the introduction of generic versions [4]. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceuticals.
Who makes generic teriparatide?
Several pharmaceutical companies manufacture and market generic versions of teriparatide. These include manufacturers like Teva Pharmaceuticals, Apotex, and others who have received FDA approval to sell their teriparatide products in the United States [3].
What are the risks and side effects of teriparatide?
Teriparatide carries certain risks and potential side effects. Common side effects include nausea, joint pain, headache, and dizziness. More serious potential risks include osteosarcoma (a type of bone cancer), although this has primarily been observed in rodent studies and its relevance to humans is not fully established [1]. Patients are advised to discuss any concerns with their healthcare provider.
How is teriparatide administered?
Teriparatide is administered as a daily subcutaneous injection, typically in the thigh or abdomen [1]. The injection device is usually a pen injector, similar to those used for insulin.
What clinical data supports teriparatide's efficacy?
Clinical trials have demonstrated teriparatide's efficacy in reducing the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Studies also show increases in bone mineral density [1].
How does teriparatide work?
Teriparatide works by stimulating osteoblasts, the cells responsible for bone formation, and increasing osteoblast activity and number. It also has effects on bone resorption, but its net effect is an increase in bone mass and strength [1].
What are the alternatives to teriparatide?
Other osteoporosis treatments include bisphosphonates (e.g., alendronate, risedronate), denosumab (Prolia), romosozumab (Evenity), and hormone replacement therapy. The choice of treatment depends on individual patient factors, fracture risk, and other medical conditions [5].